1 / 28

Hepatitis A and Hepatitis A Vaccine

Hepatitis A and Hepatitis A Vaccine. Epidemiology and Prevention of Vaccine-Preventable Diseases National Immunization Program Centers for Disease Control and Prevention. Revised March 2002. Hepatitis A. Epidemic jaundice described by Hippocrates Differentiated from hepatitis B in 1940s

eglaze
Télécharger la présentation

Hepatitis A and Hepatitis A Vaccine

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Hepatitis A and Hepatitis A Vaccine Epidemiology and Prevention of Vaccine-Preventable Diseases National Immunization Program Centers for Disease Control and Prevention Revised March 2002

  2. Hepatitis A • Epidemic jaundice described by Hippocrates • Differentiated from hepatitis B in 1940s • Serologic tests developed in 1970s • Most commonly reported type of hepatitis in the United States

  3. Hepatitis A Virus • Picornavirus (RNA) • Humans are only natural host • Stable at low pH • Inactivated by high temperature, formalin, chlorine

  4. Hepatitis A Pathogenesis • Entry into mouth • Viral replication in the liver • Virus present in blood and feces 10-12 days after infection • Virus excretion may continue for up to 3 weeks after onset of symptoms

  5. Hepatitis A Clinical Features • Incubation period 28 days (range 15-50 days) • Illness not specific for hepatitis A • Likelihood of symptomatic illness directly related to age • Children generally asymptomatic, adults symptomatic

  6. Hepatitis A Epidemiology • Reservoir Human. Endemic • Transmission Fecal-oral • Temporal pattern None • Communicability 2 weeks before to 1 week after onset

  7. Source of Hepatitis A Infection

  8. Vaccine Licensed Hepatitis A – United States, 1966-2001* *2001 provisional data

  9. Hepatitis A Incidence* by Age Group *rate per 100,000 population. 1997 data.

  10. Vaccine Licensed ACIP Recommendation Hepatitis A Incidence - United States and American Indians, 1990-2000 American Indians United States Source: National Notifiable Diseases Surveillance System, CDC

  11. Hepatitis A Vaccines • Inactivated whole virus • HAVRIX (GlaxoSmithKline) • VAQTA (Merck Vaccine Division) • Pediatric and adult formulations • Licensed for persons >2 years

  12. Formulation Pediatric age dose Adult age dose HAVRIX 2-18 yrs 0.5 ml >18 yrs 1.0 ml VAQTA 2-18 yrs 0.5 ml >18 yrs 1.0 ml Hepatitis A Vaccines

  13. Hepatitis A VaccineImmunogenicity • 95% seropositive after one dose • 100% seropositive after two doses • >97% seropositive after one • 100% seropositive after 2 doses Adults Children (>2 years) and Adolescents

  14. Hepatitis A Vaccine Efficacy • 40,000 Thai children 4-15 years • Vaccine efficacy 94% • 1,000 children 2-16 years • Vaccine efficacy 100% GlaxoSmithKline Merck

  15. Hepatitis A Vaccines • 1 dose • Booster dose 6 - 18 months after first dose • 1 dose • Booster dose 6 - 18 months after first dose Adult Children and Adolescent

  16. Hepatitis A Vaccine Recommendations • Children >2 years in states, counties, or communities where the average annual hepatitis A rate during 1987-1997 was >20 per 100,000 population Routine hepatitis A vaccination is recommended for:

  17. Hepatitis A Vaccination StrategiesHigh Incidence States • One or more single age cohorts of children or adolescents • Children in settings such as day care • Children and adolescents in a wide range of ages in a variety of settings, such as when they seek health care for other purposes

  18. Hepatitis A Vaccine Recommendations • Children >2 years in states, counties, or communities where the average annual hepatitis A rate during 1987-1997 was 10 to 20 per 100,000 population Routine hepatitis A vaccination should be considered for:

  19. Hepatitis A Vaccination StrategiesIntermediate Incidence States • Statewide or community-based? • Clustering of high-incidence areas within the state • Feasibility • Impact on incidence

  20. Hepatitis A – High Incidence States

  21. Twinrix • Combination hepatitis B (adult dose) and hepatitis A vaccine (pediatric dose) • Schedule: 0, 1, 6-12 months • Approved for persons >18 years

  22. Hepatitis A VaccineRecommendations • International travelers • Men who have sex with men • Drug users • Persons with occupational risk • Persons with chronic liver disease, including hepatitis C

  23. Hepatitis A VaccineRecommendations • Travelers to high or intermediate risk countries • Protected by 4 weeks after dose • Give concurrent IG for travel in <4 weeks

  24. Hepatitis A VaccineRecommendations • Health care workers: not routinely recommended • Day care centers: not routinely recommended • Food handlers: may be considered based on local circumstances

  25. Hepatitis A Serologic Testing • Not indicated for children • May be considered for some adults and older adolescents • Not indicated Prevaccination Postvaccination

  26. Hepatitis A VaccineAdverse Reactions • Pain at injection site • Systemic reactions uncommon • No serious adverse events reported

  27. Hepatitis A VaccineContraindications and Precautions • Severe allergy to vaccine component or following prior dose • Moderate or severe acute illness

  28. National Immunization Program • Hotline 800.232.2522 • Email nipinfo@cdc.gov • Website www.cdc.gov/nip

More Related